Kaleido Biosciences, Inc. (KLDO)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Kaleido Biosciences, Inc. (KLDO) with AI Score 48/100 (Weak). Kaleido Biosciences, Inc. is a clinical-stage healthcare company focused on developing microbiome metabolic therapies. Market cap: $0, Sector: Healthcare.
Last analyzed: Mar 15, 2026Kaleido Biosciences, Inc. (KLDO) Healthcare & Pipeline Overview
Kaleido Biosciences, Inc., a clinical-stage biotechnology company, pioneers microbiome metabolic therapies targeting a range of diseases. Their pipeline includes treatments for urea cycle disorder, ulcerative colitis, hepatic encephalopathy, and COVID-19. The company collaborates with research institutions and aims to address unmet needs in various therapeutic areas.
Investment Thesis
Kaleido Biosciences, Inc. is focused on developing microbiome metabolic therapies, representing a novel approach to treating various diseases. The company's pipeline includes clinical-stage assets targeting urea cycle disorder, ulcerative colitis, hepatic encephalopathy, and COVID-19. However, with a negative profit margin of -8178.3% and gross margin of -113.6%, the company faces significant financial challenges. Potential investors should carefully consider the risks associated with clinical-stage biotechnology companies, including regulatory hurdles, clinical trial outcomes, and funding requirements. The company's collaborations with research institutions may provide validation and support for its technology.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap: $0.00B indicates the company's small size and potential volatility.
- P/E Ratio: -0.00 reflects the company's lack of profitability.
- Profit Margin: -8178.3% highlights the company's significant losses.
- Gross Margin: -113.6% indicates that the company's cost of goods sold exceeds its revenue.
- Beta: -1.17 suggests the stock is less volatile than the market.
Competitors & Peers
Strengths
- Novel microbiome metabolic therapy platform.
- Clinical-stage pipeline with multiple programs.
- Collaborations with leading research institutions.
- Potential to address unmet needs in various disease areas.
Weaknesses
- Negative profit margin and gross margin.
- Dependence on clinical trial outcomes and regulatory approvals.
- Limited financial resources.
- High research and development costs.
Catalysts
- Upcoming: Clinical trial results for KB195 in urea cycle disorder.
- Upcoming: Clinical trial results for KB295 in ulcerative colitis.
- Upcoming: Clinical trial results for KB174 in hepatic encephalopathy.
- Upcoming: Clinical trial results for KB109 in COVID-19 disease.
- Ongoing: Potential for new collaborations with pharmaceutical companies.
Risks
- Potential: Unfavorable clinical trial outcomes.
- Potential: Regulatory hurdles and delays.
- Potential: Competition from other biotechnology and pharmaceutical companies.
- Ongoing: Limited financial resources.
- Ongoing: High research and development costs.
Growth Opportunities
- Expansion of Clinical Pipeline: Kaleido Biosciences has the opportunity to expand its clinical pipeline by developing new microbiome metabolic therapies for additional diseases. The market for microbiome-based therapies is expected to grow significantly in the coming years, driven by increasing understanding of the role of the microbiome in human health and disease. This expansion could target areas such as autoimmune diseases or neurological disorders, leveraging the existing platform.
- Strategic Collaborations: Kaleido Biosciences can leverage strategic collaborations with pharmaceutical companies and research institutions to accelerate the development and commercialization of its therapies. Collaborations can provide access to funding, expertise, and resources, as well as potential partnerships for commercialization. The company already has collaborations with Institute Gustave Roussy, Washington University, and Janssen.
- Regulatory Approvals: Successful regulatory approvals of its clinical-stage assets, such as KB195, KB295, KB174, and KB109, would be a significant growth driver for Kaleido Biosciences. Regulatory approvals would allow the company to commercialize its therapies and generate revenue. The timeline for regulatory approvals depends on the outcome of clinical trials and the regulatory review process.
- Market Penetration: Kaleido Biosciences can focus on market penetration for its approved therapies by targeting specific patient populations and geographic regions. Effective marketing and sales strategies are essential for driving adoption of its therapies. This includes educating healthcare providers and patients about the benefits of microbiome metabolic therapies.
- Intellectual Property Protection: Strengthening and expanding its intellectual property portfolio is crucial for protecting its competitive advantage. Strong patent protection can prevent competitors from developing and commercializing similar therapies. This involves actively pursuing new patents for its technologies and defending its existing patents against infringement.
Opportunities
- Expansion of clinical pipeline.
- Strategic collaborations with pharmaceutical companies.
- Successful regulatory approvals of its therapies.
- Market penetration in specific patient populations.
Threats
- Competition from other biotechnology and pharmaceutical companies.
- Unfavorable clinical trial outcomes.
- Regulatory hurdles and delays.
- Patent challenges and intellectual property disputes.
Competitive Advantages
- Proprietary microbiome metabolic therapy platform.
- Patent protection for its therapies.
- Clinical data supporting the safety and efficacy of its therapies.
- Collaborations with leading research institutions.
About KLDO
Kaleido Biosciences, Inc., founded in 2015 and headquartered in Lexington, Massachusetts, is a clinical-stage healthcare company dedicated to developing microbiome metabolic therapies. The company's approach focuses on modulating the metabolic output and activity of the microbiome to treat various diseases. Their pipeline includes KB195 for urea cycle disorder, KB295 for ulcerative colitis, KB174 for hepatic encephalopathy, and KB109 for COVID-19. These therapies are designed to address unmet needs in these specific disease areas. Kaleido Biosciences also has ongoing programs targeting multi-drug resistant infections, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company collaborates with leading research institutions such as the Institute Gustave Roussy, Washington University, and Janssen to advance its research and development efforts. Kaleido Biosciences aims to leverage the potential of the microbiome to develop innovative therapies for a wide range of diseases.
What They Do
- Develop microbiome metabolic therapies.
- Target urea cycle disorder with KB195.
- Develop KB295 to treat ulcerative colitis.
- Develop KB174 for the treatment of hepatic encephalopathy.
- Develop KB109 to treat COVID-19 disease.
- Develop programs for multi drug resistant infection.
- Develop programs for chronic kidney disease.
- Develop programs for atherosclerotic cardiovascular disease.
Business Model
- Develop and patent microbiome metabolic therapies.
- Conduct clinical trials to evaluate the safety and efficacy of its therapies.
- Seek regulatory approvals from agencies like the FDA.
- Commercialize approved therapies through partnerships or direct sales.
Industry Context
Kaleido Biosciences operates in the competitive biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The company focuses on microbiome metabolic therapies, a relatively new and rapidly evolving field. The industry is driven by increasing demand for innovative therapies for various diseases, including metabolic disorders, inflammatory diseases, and infectious diseases. Kaleido Biosciences competes with other biotechnology companies, pharmaceutical companies, and research institutions in the development and commercialization of microbiome-based therapies.
Key Customers
- Patients with urea cycle disorder.
- Patients with ulcerative colitis.
- Patients with hepatic encephalopathy.
- Patients with COVID-19 disease.
- Healthcare providers who prescribe the company's therapies.
Financials
Chart & Info
Kaleido Biosciences, Inc. (KLDO) stock price: Price data unavailable
Latest News
No recent news available for KLDO.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for KLDO.
Price Targets
Wall Street price target analysis for KLDO.
MoonshotScore
What does this score mean?
The MoonshotScore rates KLDO's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Leadership: Mark A. Wingertzahn
CEO
Mark A. Wingertzahn is the CEO of Kaleido Biosciences, Inc. His professional background and educational details are not available in the provided data. As CEO, he is responsible for leading the company's strategic direction and overseeing its operations. He manages a team of 76 employees.
Track Record: Information about Mark A. Wingertzahn's specific achievements, strategic decisions, and company milestones under his leadership is not available in the provided data. His tenure at Kaleido Biosciences is also unknown.
KLDO OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that the company may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited information available to investors and may be subject to greater risks. Investing in companies on the OTC Other tier is generally considered more speculative due to the lack of regulatory oversight and transparency compared to exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited information and transparency.
- Lower regulatory oversight compared to listed exchanges.
- Potential for price manipulation and fraud.
- Higher risk of delisting or bankruptcy.
- Limited liquidity and wider bid-ask spreads.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent protection.
- Review the company's legal and regulatory compliance.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Existence of a clear business plan and strategy.
- Experienced management team with relevant expertise.
- Partnerships with reputable organizations.
- Positive clinical trial results (if applicable).
- Active engagement with investors and stakeholders.
KLDO Healthcare Stock FAQ
What does Kaleido Biosciences, Inc. do?
Kaleido Biosciences, Inc. is a clinical-stage healthcare company focused on developing microbiome metabolic therapies. Their approach involves modulating the metabolic output and activity of the microbiome to treat various diseases. The company's pipeline includes therapies targeting urea cycle disorder, ulcerative colitis, hepatic encephalopathy, and COVID-19. Kaleido Biosciences aims to leverage the potential of the microbiome to develop innovative therapies for a wide range of diseases, addressing unmet medical needs.
What do analysts say about KLDO stock?
As of March 15, 2026, analyst ratings and price targets for KLDO stock are unavailable due to the pending update of stock data. Investors should conduct their own due diligence and consider the company's financial performance, clinical trial results, and regulatory milestones when evaluating the stock. Key valuation metrics, such as price-to-earnings ratio and price-to-sales ratio, are not applicable due to the company's lack of profitability.
What are the main risks for KLDO?
The main risks for Kaleido Biosciences, Inc. include the inherent uncertainties of clinical-stage drug development, such as unfavorable clinical trial outcomes and regulatory hurdles. The company's limited financial resources and high research and development costs also pose significant risks. Competition from other biotechnology and pharmaceutical companies, as well as potential patent challenges, could also impact the company's success. Investing in KLDO involves a high degree of risk due to its OTC market status and negative profitability.
What are the key factors to evaluate for KLDO?
Kaleido Biosciences, Inc. (KLDO) currently holds an AI score of 48/100, indicating low score. Key strength: Novel microbiome metabolic therapy platform.. Primary risk to monitor: Potential: Unfavorable clinical trial outcomes.. This is not financial advice.
How frequently does KLDO data refresh on this page?
KLDO prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven KLDO's recent stock price performance?
Recent price movement in Kaleido Biosciences, Inc. (KLDO) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Novel microbiome metabolic therapy platform.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider KLDO overvalued or undervalued right now?
Determining whether Kaleido Biosciences, Inc. (KLDO) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying KLDO?
Before investing in Kaleido Biosciences, Inc. (KLDO), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Stock data pending update.
- Limited information available on CEO track record.